Seamus Mulligan bought $10.0M of JAZZ
director at Jazz Pharmaceuticals plc. 101,621 shares at an average of $98.34, traded May 9, 2025, filed May 13, 2025.
Score components
- +15RoleDirector
- +25Trade size$10.0M at market
- +8Relative to holdingsFirst purchase: no shares before this trade
- +18Price context0% above the 52-week low; 32% below the 52-week high
- 0ClusterNo other insider buying within 14 days
- 0Repeat buyingFirst buy in 90 days
- 0Track recordToo few past buys to judge (0 with prices)
What happened after comparable buys
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001765581-25-000042, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| May 9, 2025 | POpen-market purchase Ordinary Sharesindirect: By Nerano Pharma Lim | +80,684 | $98.10 | $7.9M | 80,684 | May 13, 2025 |
| May 9, 2025 | POpen-market purchase Ordinary Sharesindirect: By Nerano Pharma Lim | +19,216 | $98.91 | $1.9M | 99,900 | May 13, 2025 |
| May 9, 2025 | POpen-market purchase Ordinary Sharesindirect: By Nerano Pharma Lim | +100 | $99.71 | $9,971 | 100,000 | May 13, 2025 |
| May 12, 2025 | POpen-market purchase Ordinary Sharesindirect: By Nerano Pharma Lim | +1,621 | $103.00 | $167k | 101,621 | May 13, 2025 |
Related signals
Other insiders at Jazz Pharmaceuticals plc and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 30Weak | Jazz Pharmaceuticals plc | Renee D Gala President & CEO | $473k 2,000 shares | -1% | |
| 28Weak | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.4M 6,000 shares | -2% | |
| 24Weak | Jazz Pharmaceuticals plc | Neena M Patil EVP & Chief Legal Officer | $289k 1,200 shares | -2% | |
| 38Weak | Jazz Pharmaceuticals plc | Renee D Gala President & CEO | $486k 2,000 shares | -1% | |
| 45Moderate | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $1.5M 6,000 shares | -2% | |
| 50Moderate | Jazz Pharmaceuticals plc | Patricia Carr SVP, Chief Accounting Officer | $798k 4,660 shares | -65% | |
| 38Weak | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $14M 77,500 shares | -16% | |
| 48Moderate | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $3.3M 18,000 shares | -4% | |
| 53Moderate | Jazz Pharmaceuticals plc | Patricia Carr SVP, Chief Accounting Officer | $968k 5,319 shares | -75% | |
| 17Weak | Jazz Pharmaceuticals plc | Bruce C Cozadd Chairman & CEO | $754k 5,500 shares | -1% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.